Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 291

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 291
---
R currently has ongoing collaborations with: The Trustees of the University
of Pennsylvania, Alzheimer’s Therapeutic Research Institute of University of Southern California, Brain Health Imaging Institute
of Weill Cornell Medicine (BHII), and New York University School of Medicine. These institutions provide DiamiR with well-characterized
plasma samples and associated demographic and clinical data for the analysis.

DiamiR previously collaborated with The Roskamp
Institute Memory Center, Sarasota, FL; Washington University Alzheimer’s Disease Research Center; Center for Neurodegenerative Disease
Research at University of Pennsylvania; Alzheimer’s Disease Cooperative Study (ADCS) Biomarker Core at University of California,
San Diego (UCSD); Tri-State Rett Syndrome Center at Montefiore Medical Center, Albert Einstein College of Medicine; and New York Blood
Center, Inc.

These organizations have provided, and may continue
to provide, DiamiR with plasma samples, and accompanying clinical data as available, including disease status, patient demographics, neuroimaging
data, CSF biomarkers analysis, cognitive assessment parameters, and accompanying diseases outcomes. DiamiR works, and will continue to
work, closely with the researchers and physicians at the centers to ensure that the available clinical data is properly interpreted.

Intellectual Property

DiamiR relies on proprietary technologies and
product branding. Its policy is to seek patent protection domestically and internationally and trademark registration for valuable assets,
as appropriate, and maintain other aspects of its proprietary platform, processes, and know-how as trade secrets.

In February 2014 the United States Patent and
Trademark Office (USPTO) issued U.S. Patent No. 8,648,017, entitled “Methods of using small RNA from bodily fluids for diagnosis
and monitoring of neurodegenerative diseases.” The patent, which is set to expire in November 2030, claims the use of methods developed
by DiamiR for early detection and diagnosis of neurodegenerative diseases (NDs).

In total, DiamiR has seven families of issued patents.

<div align='center'>153</div>

The table below contains the patent
listing and country of issue for all of DiamiR’s 52 issued patents. DiamiR has an obligation to pay annual fees to keep these patents
active in the different territories that have issued the patents.

<div align='center'>Current DiamiR Patents Issued or Allowed</div>

Intellectual Property

The following provides a general description of
DiamiR’s patent portfolio and is